magnevist and Oragrafin sodium Interactions

Interactions between magnevist(gadopentetate dimeglumine) and Oragrafin sodium (ipodate)

ipodate and gadopentetate dimeglumine (Moderate Drug-Drug)

ADJUST DOSING INTERVAL: Renal toxicity has been reported in a few patients with liver dysfunction who were given an oral cholecystographic agent followed by intravenous contrast agents. The mechanism of interaction has not been described.

MANAGEMENT: Administration of any intravascular contrast agent should be deferred for 48 hours in patients with hepatic or biliary disorders who have recently received an oral cholecystographic contrast agent.